logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN
prime DX

prime DX

The prime DX new technology for tumor molecular profiling is compatible with both FFPE and PLASMA.

Prime DX is designed to give to the physician an overall outlook on treatment response for:
• Targeted therapy
• Immunotherapy
• Chemotherapy

Learn more
HerediGENE

HerediGENE

HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are responsible for increased risk of developing breast, ovarian and other hereditary cancers.

Learn more
OncotypeDX<sup>®</sup><br /> Breast

OncotypeDX®
Breast

The OncotypeDX® breast cancer test is a diagnostic test created to help patients who have been recently diagnosed with early stage, estrogen receptor positive breast cancer.

Learn more
Com.Pl.i.t. DX<br/> Assay

Com.Pl.i.t. DX
Assay

Com.Pl.i.t. DX Assay is a multigene test designed to help you and your physician make informed treatment decisions based on the unique biology of your tumor and individualize your treatment.

Learn more
cloud
cloud

Services

Molecular Genetics

Genekor is specialized in molecular genetics.

Utilizing cutting edge technology, our company offers all the validated molecular tools for the diagnosis, prognosis and individualized treatment.

cloud
cloud

Services

Oncology, Cardiology, Neurology and Pharmacogenetics

We focus on oncology, cardiology, neurology and pharmacogenomics. Our goal is to achieve the most direct, most valid and most economical diagnostic procedure in order to generally improve patient care.

Company

Genekor

GeneKor is multinational molecular diagnostics company founded in 2007 and operates molecular biology laboratories with state of the art equipment suitable to provide the highest quality of Molecular Services . We provide a diversification of services focused on improving patient care utilizing the latest technologies of prognostic, predictive, and personalized medicine.

The clinical expertise of GeneKor focuses on:

  • Response to Targeted Therapy
  • Pharmacogenetics
  • Determination of Hereditary Cancer (Breast Cancer , Colon Cancer , Thyroid Cancer , Pancreatic Cancer , etc.)
  • New Unique Technological Platforms (OncotypeDX BreastTM, OncotypeDX ColonTM, OncotypeDX ProstateTM, PCA3TM)

Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing

Konstantinos Agiannitopoulos 1,*,Kevisa Potska 1,Anastasia Katseli 1,Christina Ntogka 1,Georgios N. Tsaousis 1ORCID,Georgia Pepe 1,Dimitra Bouzarelou 1,Nikolaos Tsoulos 1ORCID,Athanasios Papathanasiou 1ORCID,Dimitrios Ziogas 2ORCID,Vassileios Venizelos 3,Christos Markopoulos 4,Rodoniki Iosifidou 5,Sofia Karageorgopoulou 6,Stylianos Giassas 6,Ioannis Natsiopoulos 7,Konstantinos Papazisis 8,Maria Vasilaki-Antonatou 9,Amanta Psyrri 10,Anna Koumarianou 10ORCID,Dimitrios Matthaios 11,Eleni Zairi 12,Alexandru Blidaru 13,Eugeniu Banu 14,Dan Corneliu Jinga 15,Şahin Laçin 16,Mustafa Özdoğan 17,Eirini Papadopoulou 1 and George Nasioulas

Aggianitopoulos et al. 2023_Cancers

RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis

AIKATERINI TSANTIKIDI1 , KONSTANTINOS PAPAZISIS2 , THEOFANIS FLOROS3 , MARIA GAZOULI4 , EIRINI PAPADOPOULOU1 , GEORGIOS TSAOUSIS1 , GEORGIOS NASIOULAS1 , ANDRA MESTER5 , KUBELAC PAUL MILAN5 , BOGDAN GOZMAN6 , VLAD AFRASANIE6 , DANA LUCIA STANCULEANU7 , OANA TRIFANESCU7 , FLORENTINA PESCARU8 , CLAUDIA MILITARU9 and CHRISTOS PAPADIMITRIOU1

Tsantikidi et al

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing

KONSTANTINOS AGIANNITOPOULOS1, GEORGIA PEPE1, GEORGIOS N. TSAOUSIS1, KEVISA POTSKA1, DIMITRA BOUZARELOU1, ANASTASIA KATSELI 1, CHRISTINA NTOGKA1, ANGELIKI MEINTANI 1, NIKOLAOS TSOULOS1, STYLIANOS GIASSAS2, VASSILEIOS VENIZELOS3, CHRISTOS MARKOPOULOS4, RODONIKI IOSIFIDOU5, SOFIA KARAGEORGOPOULOU2, CHRISTOS CHRISTODOULOU3, IOANNIS NATSIOPOULOS6, KONSTANTINOS PAPAZISIS7, MARIA VASILAKI-ANTONATOU8, ELEFTHERIOS KABLETSAS9, AMANTA PSYRRI 10, DIMITRIOS ZIOGAS11, EFTHALIA LALLA4, ANNA KOUMARIANOU10, KORNILIA ANASTASAKOU3, CHRISTOS PAPADIMITRIOU12, VAHIT OZMEN13, SUALP TANSAN14, KERIM KABAN15, TAHSIN OZATLI 16, DAN TUDOR ENIU17, ANGELICA CHIOREAN18, ALEXANDRU BLIDARU19, MARRIT RINSMA20, EIRINI PAPADOPOULOU1 and GEORGE NASIOULAS1

K. Agiannitopoulos et al 2023
Change cookies consent Revoke cookies consent